KEY TAKEAWAYS
- The study aimed to compare effectiveness and toxicity and evaluate POCRT versus PORT in patients with HNACC.
- POCRT may offer improved local control in HNACC patients over PORT alone but with increased treatment-related toxicity.
Zichen Qiu and the team conducted a study that aimed to evaluate the efficacy and side effects of platinum-based adjuvant chemoradiotherapy (POCRT) versus postoperative radiotherapy (PORT) in head and neck adenoid cystic carcinoma (HNACC) patients.
This retrospective study analyzed patients diagnosed with HNACC at the center between January 2010 and April 2020. A matched cohort was created using a 1:1 propensity score matching method.
About 206 patients were included, 147 (71.4%) undergoing PORT and 59 (28.6%) receiving POCRT. Among them, 21 patients encountered local-regional failure. The local-regional control (LRC) rates at 3, 5, and 10 years for the entire cohort stood at 92.0%, 90.6%, and 86.9%, respectively.
Notably, in both the overall and matched cohorts, the POCRT group demonstrated superior LRC compared to the PORT group (Gray’s test, all P< 0.05*). Furthermore, multivariate analysis revealed adjuvant concurrent chemotherapy as an independent prognostic factor for LRC (Competing risks regression, HR = 0.144, 95% CI 0.026-0.802, P= 0.027*).
Additionally, the POCRT group exhibited higher incidences of upper gastrointestinal toxicity and hematologic toxicities, including leukopenia, neutropenia, and anemia (all P< 0.05*).
The study suggested that POCRT may present a potentially superior therapeutic option over PORT alone in reducing locoregional failures among patients with HNACC. However, this advantage comes with an augmented burden of treatment-related toxicity.
No funding was provided.
Source: https://pubmed.ncbi.nlm.nih.gov/38625410/
Qiu Z, Wu Z, Zhou X, et al. (2024) “Platinum-based adjuvant chemoradiotherapy versus adjuvant radiotherapy in patients with head and neck adenoid cystic carcinoma. J Cancer Res Clin Oncol. 2024 Apr 16;150(4):195. doi: 10.1007/s00432-024-05719-0. PMID: 38625410.
